linjc16/ctgov huggingface dataset:
Pulse Diagnoses in Patients While Dysmenorrhea is Attacking

Study Overview
=================
Brief Summary
-----------------
The mechanism led to the dysmenorrhea can be understood more clearly and one may have a better idea to treat the disease in the future.

Detailed Description
-----------------
Background: Pulse diagnosis of the dysmenorrhea patients before and after acupuncture treatment on the acupoint San Yin Jiao (SP6) were performed so that the mechanism led to the pain can be understood more clearly and one may have a better idea to treat the disease in the future. Methods: Fifteen women participated in the study voluntarily. They have first to fill in the form of Visual Analogue Scale (VAS) for pain. Then the pulse of the subjects were measured by ANSWatch before and after acupuncture. All meridians can be assessed by analyzing the pulse spectra through Fast Fourier Transform (FFT) of the original pulse data. The significant change of amplitude in certain harmonics which corresponds to a specific meridian after acupuncture treatment can be selected out.

Official Title
-----------------
The Effect of Acupuncture Treatment of Acupoint San Yin Jiao on the Pulse Diagnoses in Patients While Dysmenorrhea is Attacking

Conditions
-----------------
Dysmenorrhea

Intervention / Treatment
-----------------
* Diagnostic Test: ANSWatch


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The inclusion criteria of the subjects were the presence of pain during menstruation or three days before it. It needed to recheck if the menstrual cycle appeared within three days after recruiting if dysmenorrhea attacked before menstruation. Exclusion Criteria: The exclusion criterion was that subjects did not take pain killers in the 12 hours before measurement.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: ANSWatch|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients' radial artery pulses. Change is being assessed. | Get subjects' pulses by ANSWatch | Measure subjects' radial artery pulses before and after acupuncture in 10 minutes respectively. |
Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

Study Overview
=================
Brief Summary
-----------------
The study will assess the role of high-dose imatinib mesylate, in patients who have taken imatinib mesylate for at least 1 year at the standard dose, in achieving a major molecular response (a measure of the level of chronic myelogenous leukemia) versus the standard dose.

Official Title
-----------------
Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Ph+ CML

Conditions
-----------------
Chronic Myelogenous Leukemia

Intervention / Treatment
-----------------
* Drug: imatinib mesylate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic myelogenous leukemia with Philadelphia chromosome 18 years and older Patients must have been taking imatinib mesylate standard dose for at least 12 months and have achieved a complete cytogenetic response but not a major molecular response. Exclusion Criteria: Patients with cardiac problems such as congestive heart failure, or myocardial infarction within the last 6 months Patients with an uncontrolled medical disease such as uncontrolled diabetes, chronic renal (kidney) disease or active uncontrolled infection. Patients with other current primary malignancy or malignancy requiring active intervention Other protocol defined inclusion/exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: STI571<br> | Drug: imatinib mesylate<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percent of patients achieving major molecular response at baseline and at last visit |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Complete cytogenetic response at baseline and at last visit |  |  | 
| Overall survival |  |  | 
| Disease progression-free survival |  |  | 
| Quality of Life assessment at baseline, last visit |  |  | 
| Safety: adverse events and lab parameters, vital signs, physical exam, electrocardiogram, concomitant medications |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic Myelogenous Leukemia, Complete cytogenetic response, Imatinib mesylate, Major molecular response, Chronic phase Ph+ Chronic Myelogenous Leukemia
Bioburden Reduction of Diabetic Foot Ulcer

Study Overview
=================
Brief Summary
-----------------
Study to see if a laser can get rid of bacateria called MRSA in your diabetic ulcer

Official Title
-----------------
Noveon Laser Treatment to Effect Bioburden Reduction or Elimination in Diabetic Foot Ulcer: A Davice Performance Clinical Study

Conditions
-----------------
Diabetic Foot Ulcer

Intervention / Treatment
-----------------
* Device: Noveon laser


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18 and older Diabetic foot ulcer MRSA positive Exclusion Criteria:osteomylelitis pregnancy allery to e mycin -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Noveon laser|870 and 930nm wavelengths|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Decrease of Bioburden Effect In diabetic Foot Ulcer |  | 28 days |
REgistry on Real-Life EXperience With Left Atrial Appendage Occlusion

Study Overview
=================
Brief Summary
-----------------
The objective of this observational non-randomized multicenter study is to compile real-world clinical characteristics and outcomes data for patients treated with LAA (left atrial appendage) closure systems in a daily clinical setting.

Official Title
-----------------
REgistry on Real-Life EXperience With Left Atrial Appendage Occlusion for Patients With Atrial Fibrillation in France

Conditions
-----------------
Atrial Fibrillation

Intervention / Treatment
-----------------
* Device: Percutaneous Left Atrial Appendage Occlusion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who are eligible for a LAA occlusion device and treated with a commercially available device according to international and local guidelines and per physician discretion. Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Percutaneous Left Atrial Appendage Occlusion|Percutaneous left atrial appendage occlusion in routine care for patients with atrial fibrillation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major adverse cardiovascular events | Death, Ischemic stroke, Transient ischemic attack, Major hemorrhage, Thrombus on device | From date of inclusion until the date of first documented event, whichever came first, assessed up to 60 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Atrial fibrillation, Stroke, Thrombus, Left atrial appendage, Bleeding
Study to Compare a Fast Gama Camera for Nuclear Imaging to Conventional Camera

Study Overview
=================
Brief Summary
-----------------
A feasibility trial to evaluate the usefulness of a high efficiency camera (D-SPECT) as an imaging modality for general nuclear medicine applications such as oncology.

Official Title
-----------------
Evaluation of Multi Purpose D-spect Camera for General Nuclear Scans

Conditions
-----------------
Detect Pathalogical Lesions

Intervention / Treatment
-----------------
* Device: GP-D-SPECT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is referred to nuclear medicine department for a SPECT scan. Written informed consent is obtained by a study investigator. Exclusion Criteria: Patient pregnancy (known or suspected). Lack of written informed consent Prisoner status Patient under age 18 or over 80 years old.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: GP-D-SPECT|The D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large PMTs. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A comparison of high efficiency camera images (D-SPECT) to a conventional camera (A-SPECT) with respect to the ability to detect pathological lesions. |  | 12 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A comparison of high efficiency camera images (D-SPECT) to a conventional camera (A-SPECT) with respect to image quality/resolution |  | 12 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Whole body, SPECT
Dairy Intake and Brain Health in Aging

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to learn if dairy food consumption may help brain health in aging by protecting nerve cells from oxidative damage.

Official Title
-----------------
Dairy Intake and Brain Health in Aging

Conditions
-----------------
Aged Healthy Volunteer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females between 60-85 years of age. Good general health with no concomitant diseases, which would be expected to interfere with the study BMI range 20-35 kg/m2 Exclusion Criteria: Presence of any central neurological disease with the potential to impair cognition(e.g., brain tumor, stroke, epilepsy, motor neuron disease, multiple sclerosis, Alzheimer disease, Parkinson's disease) or prior major head trauma with loss of consciousness Presence of an active unstable and life-threatening systemic illness (e.g., cancer) Presence of major psychiatric disorder within the past 3 years including depression, anxiety, and alcohol (over 3 drinks per day or total of 18 per week) or drug abuse (DSM-IV criteria; Geriatric Depression Score>6) Presence of diabetes mellitus (defined as a clinical diagnosis or use of an anti-diabetic agent) and metabolic syndrome Use of psychoactive and investigational medications Subjects with MRI contraindications such as pacemaker, aneurysm clips, artificial heart valves, metal fragments, foreign objects or claustrophobia. All subjects subjects will receive a structural MRI as part of this study. Individuals with evidence of infection, infarction, neoplasm or other lesions will be excluded. Individuals found to have abnormalities in their structural MRI will be referred to their primary physician for further evaluation and management. Pregnancy Special diet regimens such as lactose free or vegan

Ages Eligible for Study
-----------------
Minimum Age: 60 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Low dairy intake<br>1 serving/day or less of dairy food characterized at enrollment using 24 hr dietary recall | |
| Moderate Dairy Intake<br>1-2 servings/day of dairy food characterized at enrollment using 24 hr dietary recall | |
| Recommended Dairy Intake<br>Greater than 3 servings/day of dairy food characterized at enrollment using 24 hr dietary recall | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Cerebral glutathione (GSH) levels measured by magnetic resonance spectroscopy (MRS) |  | Baseline | 
| Dietary dairy food intake measured using 7-day diet recording |  | 1 week, prior to MRS scan | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Glutathione, Dairy consumption, Brain, Humans
Changes in Inter-joint Coordination and Muscle Activation After Cruciate Ligament Injury of the Knee Joint

Study Overview
=================
Brief Summary
-----------------
Stair negotiation is an important activity of daily living. Patients with cruciate ligament injury may have difficulty in stair negotiation because of the proprioception deficit and neuromuscular deficit caused by ligament injury. However, the influence of knee cruciate ligament injury on the control of movement is still unclear. Since inter-joint coordination can provide the information of relationship between angle position and angle velocity, it may be useful to analysis the change of movement pattern.This current study aimed to investigate the change of inter-joint coordination and muscle activation in patients with cruciate ligament injury during stair negotiation.

Official Title
-----------------
Changes in Inter-joint Coordination and Muscle Activation After Cruciate Ligament Injury of the Knee Joint

Conditions
-----------------
To Investigate the Change of Inter-joint Coordination and Muscle Activation in Patients With Cruciate Ligament Injury During Stair Negotiation.

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: unilateral cruciate ligament injury or unilateral cruciate ligament reconstructed after 3 month able to climb up and down with step-over-step pattern BMI within 18 to 30 Exclusion Criteria: complex ligament injury lower limb fracture in recent years meniscus injury systematic disorder which would affect the balance and ambulation

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cruciate ligament group<br> | |
| control group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Evolution of Cochleovestibular Schwannomas

Study Overview
=================
Brief Summary
-----------------
Investigators want to know the natural history of the vestibular schwannomas: increasing, decreasing or stability, by monitoring more than 3 MRIs during a span of more than 2 years. They will obtain 3 groups: the volume increasing schwannomas which will be the most important group, the schwannomas that will be stable and a small group where the schwannomas will decrease. The secondary purpose is that the investigators want to know the threshold values: a minimum volume under which we are sure that the schwannoma will not increase, a maximum value where it will increase and if its evolution can be correlated to clinical or radiological criteria.

Official Title
-----------------
Evolution of Cochleovestibular Schwannomas in the Internal Auditory Canal by Volume Measering With aTeslas MRI 3

Conditions
-----------------
Schwannoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age over 18 years having a typical vestibular schwannoma diagnosis during the first MRI, having a minimum of 3 internal auditory canal MRIs on the same machine (Signa HDxt, General Electric, Strasbourg, France) ) at the Hôpitaux Universitaires de Strasbourg patients consenting to participate Exclusion Criteria: intra-labyrinthical extension treatment before the 3 MRIs no injection of gadolinium atypical diagnosis

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence or absence of intra labyrinthine vestibular nerve tumor using T2 FIESTA |  | 1 hour after the realization of the MRI | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
schwannoma, cochleovestibular schwannomas, cochleovestibular, intra labyrinthine schwannoma
Incidence Rate of Perioperiative VTE in Colorectal Cancer Patients : a Multicenter Prospective Observational Cohort Study

Study Overview
=================
Brief Summary
-----------------
This is a multi-centered, prospective, observational study aimed at observing the Incidence Rate of Perioperiative VTE in Colorectal Cancer Patients

Official Title
-----------------
Incidence Rate of Perioperiative Venous Thromboembolism(VTE) in Colorectal Cancer Patients : a Multicenter Prospective Observational Cohort Study

Conditions
-----------------
Incidence Rate of Perioperiative Venous Thromboembolism(VTE) in Colorectal Cancer Patients

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients in colorectal surgery ward Clinical diagnosis of colorectal cancer Prepare for radical colorectal surgery. Exclusion Criteria: Patients prepare for emergency surgery Clinical diagnosis of benign colorectal disease Patients who have joined other clinic studys
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Colorectal Cancer Patients<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ncidence Rate of Perioperiative VTE |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Venous Thromboembolism, Colorectal Cancer
Improvement of Range of Motion in Frozen Shoulder in Breast Cancer Survivors

Study Overview
=================
Brief Summary
-----------------
The prevalence of shoulder joint disease is high in breast cancer patients. The cause of adhesive capsulitis is not clearly identified. However, the following are known as relevant factors that are the restriction of the use of the arm after surgery, inflammation due to autoimmune action, radiation therapy, and adhesion of the surgical site. The purpose of this study is to compare and analyze the effect of intrathecal steroid injection in breast cancer survivors with adhesive capsulitis.

Official Title
-----------------
The Effectiveness of Intra-articular Steroid Injection in Breast Cancer Survivors With Adhesive Capsulitis According to the Thickness of Axillary Capsulitis Thickness

Conditions
-----------------
Breast Neoplasm, Shoulder Capsulitis, Range of Motion

Intervention / Treatment
-----------------
* Procedure: Intra-articular steroid injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who underwent breast cancer surgery within 6 months. Patients with shoulder pain and limited range of motion Exclusion Criteria: Patients with infection Bilateral shoulder pain patient Patients with uncontrolled diabetes
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: Adhesive capsulitis patients who underwent breast cancer operation
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Adhesive capsulitis in breast cancer survivors<br>Intra-articular steroid injection | Procedure: Intra-articular steroid injection<br>* Ultrasound-guided Gleno-humeral joint steroid (Triamcinolone 40mg with 0.5% lidocaine ) injection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Range of motion of shoulder joint | A goniometer is an instrument which measures the available range of motion at a joint.Flexion, Extension,Adduction,Abduction, Internal Rotation,External rotation | Change from baseline at 3 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in score on Shoulder Pain and Disability Index (SPADI) | SPADI is a scale consisting of 0-10; 0 being the best and 10 being the worse pain ever; higher scores mean a worse outcome. | Change from baseline at 3 months | 
| Axillary recess capsule thickness | Ultrasound measurements of axillary recess capsule thickness in unilateral frozen shoulder | Change from baseline at 3 months |